Catalog Number 383318 |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Bruise/Contusion (1754); Cellulitis (1768); Erythema (1840)
|
Event Date 03/09/2020 |
Event Type
Injury
|
Manufacturer Narrative
|
Unknown manufacturer: there are multiple bd locations where this unspecified bd device may have been manufactured.A catalog and lot number could not be confirmed for this incident and without this information we are unable to determine where the device was manufactured.Therefore, bd corporate headquarters in (b)(4) has been listed and the (b)(4) fda registration number has been used for the manufacture report number.Medical device expiration date: unknown.Device manufacture date: unknown.Investigation summary: as no physical sample, picture sample, or lot number was provided for evaluation by our quality engineer team, a complete investigation could not be performed.There are current quality controls in place to detect this type of product malfunction during the production process.Based on the limited investigation results, a cause for the reported incident could not be determined.Complaints received for this device and reported condition will continue to be tracked and trended.Our quality team regularly reviews the collected data for identification of emerging trends.
|
|
Event Description
|
It was reported that patient experienced redness at insertion site, bruising, and cellulitis with an unspecified bd saf-t-intima¿ iv catheter safety system.The following information was provided by the initial reporter: (3 of 3 complaints) we had incident involving patient who received administration of rituximab via the syringe pump.Patient has developed redness at the site of administration, and two of them significant expansive bruising, one with possible cellulitis and required admission.Rituximab has been given via subq using saf-t-intima and a syringe (over slow administration) initially (no reported incidents).
|
|
Event Description
|
It was reported that patient experienced redness at insertion site, bruising, and cellulitis with an bd saf-t-intima¿ iv catheter safety system.The following information was provided by the initial reporter: (3 of 3 complaints) we had incident involving patient who received administration of rituximab via the syringe pump.Patient has developed redness at the site of administration, and two of them significant expansive bruising, one with possible cellulitis and required admission.
|
|
Manufacturer Narrative
|
The following fields have been updated with additional information: a.2.Age at time of event: 71; a.2.Date of birth:(b)(6) 1949; a.3.Sex: female; b.3.Date of event: (b)(6)2020; b.5.Describe event or problem: it was reported that patient experienced redness at insertion site, bruising, and cellulitis with an bd saf-t-intima¿ iv catheter safety system.The following information was provided by the initial reporter: (3 of 3 complaints) we had incident involving patient who received administration of rituximab via the syringe pump.Patient has developed redness at the site of administration, and two of them significant expansive bruising, one with possible cellulitis and required admission.D.4 medical device catalog #: 383318.D.3.Medical device manufacturer: becton dickinson infusion therapy systems inc s.A.De c.V.¿ nogales, mexico / 84048.G.2 manufacturing location: becton dickinson infusion therapy systems inc s.A.De c.V.¿ nogales, mexico / 84048.
|
|
Search Alerts/Recalls
|
|